Literature DB >> 17253963

A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling.

Greg M Findlay1, Lijun Yan, Julia Procter, Virginie Mieulet, Richard F Lamb.   

Abstract

The mTOR (mammalian target of rapamycin) signalling pathway is a key regulator of cell growth and is controlled by growth factors and nutrients such as amino acids. Although signalling pathways from growth factor receptors to mTOR have been elucidated, the pathways mediating signalling by nutrients are poorly characterized. Through a screen for protein kinases active in the mTOR signalling pathway in Drosophila we have identified a Ste20 family member (MAP4K3) that is required for maximal S6K (S6 kinase)/4E-BP1 [eIF4E (eukaryotic initiation factor 4E)-binding protein 1] phosphorylation and regulates cell growth. Importantly, MAP4K3 activity is regulated by amino acids, but not the growth factor insulin and is not regulated by the mTORC1 inhibitor rapamycin. Our results therefore suggest a model whereby nutrients signal to mTORC1 via activation of MAP4K3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253963      PMCID: PMC1828895          DOI: 10.1042/BJ20061881

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase.

Authors:  Maya P Byfield; James T Murray; Jonathan M Backer
Journal:  J Biol Chem       Date:  2005-07-27       Impact factor: 5.157

2.  The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.

Authors:  Ewan M Smith; Stephen G Finn; Andrew R Tee; Gareth J Browne; Christopher G Proud
Journal:  J Biol Chem       Date:  2005-03-16       Impact factor: 5.157

Review 3.  Regulation of translation initiation by FRAP/mTOR.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

4.  Rheb binds and regulates the mTOR kinase.

Authors:  Xiaomeng Long; Yenshou Lin; Sara Ortiz-Vega; Kazuyoshi Yonezawa; Joseph Avruch
Journal:  Curr Biol       Date:  2005-04-26       Impact factor: 10.834

5.  Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.

Authors:  Xinsheng Gao; Yong Zhang; Peter Arrazola; Okio Hino; Toshiyuki Kobayashi; Raymond S Yeung; Binggeng Ru; Duojia Pan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

6.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Authors:  Philippe P Roux; Bryan A Ballif; Rana Anjum; Steven P Gygi; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

7.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.

Authors:  Diane C Fingar; Sofie Salama; Christina Tsou; Ed Harlow; John Blenis
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

8.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

Authors:  Attila Garami; Fried J T Zwartkruis; Takahiro Nobukuni; Manel Joaquin; Marta Roccio; Hugo Stocker; Sara C Kozma; Ernst Hafen; Johannes L Bos; George Thomas
Journal:  Mol Cell       Date:  2003-06       Impact factor: 17.970

9.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

Authors:  Brendan D Manning; Andrew R Tee; M Nicole Logsdon; John Blenis; Lewis C Cantley
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.

Authors:  Laura S Harrington; Greg M Findlay; Alex Gray; Tatiana Tolkacheva; Simon Wigfield; Heike Rebholz; Jill Barnett; Nick R Leslie; Susan Cheng; Peter R Shepherd; Ivan Gout; C Peter Downes; Richard F Lamb
Journal:  J Cell Biol       Date:  2004-07-12       Impact factor: 10.539

View more
  120 in total

Review 1.  Regulation of TOR by small GTPases.

Authors:  Raúl V Durán; Michael N Hall
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

2.  PKC-θ: hitting the bull's eye.

Authors:  Michael L Dustin
Journal:  Nat Immunol       Date:  2011-10-19       Impact factor: 25.606

Review 3.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 4.  Essential amino acid sensing, signaling, and transport in the regulation of human muscle protein metabolism.

Authors:  Jared M Dickinson; Blake B Rasmussen
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-01       Impact factor: 4.294

Review 5.  TOR-dependent control of autophagy: biting the hand that feeds.

Authors:  Thomas P Neufeld
Journal:  Curr Opin Cell Biol       Date:  2009-12-16       Impact factor: 8.382

6.  Elevated corticosterone associated with food deprivation upregulates expression in rat skeletal muscle of the mTORC1 repressor, REDD1.

Authors:  Nora K McGhee; Leonard S Jefferson; Scot R Kimball
Journal:  J Nutr       Date:  2009-03-18       Impact factor: 4.798

Review 7.  Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.

Authors:  Ken Inoki; Kun-Liang Guan
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 8.  Amino acid sensing and mTOR regulation: inside or out?

Authors:  Deborah C I Goberdhan; Margret H Ogmundsdóttir; Shubana Kazi; Bruno Reynolds; Shivanthy M Visvalingam; Clive Wilson; C A Richard Boyd
Journal:  Biochem Soc Trans       Date:  2009-02       Impact factor: 5.407

Review 9.  mTOR: dissecting regulation and mechanism of action to understand human disease.

Authors:  Deborah C I Goberdhan; C A Richard Boyd
Journal:  Biochem Soc Trans       Date:  2009-02       Impact factor: 5.407

Review 10.  mTOR regulation of autophagy.

Authors:  Chang Hwa Jung; Seung-Hyun Ro; Jing Cao; Neil Michael Otto; Do-Hyung Kim
Journal:  FEBS Lett       Date:  2010-01-18       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.